Left ventricular assist device: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>James Yolkowski
m (Lvad moved to Left Ventricular Assist Device over redirect: REMEMBER_click_move_all_subpages)
imported>Meg Taylor
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
A '''Left Ventricular Assist Device''' or '''LVAD''' is a [[pump]] which runs in parallel with a [[heart]] to boost the blood flow. The main reason for a patient to have a LVAD implanted is for [[Bridge To Transplant]] (BTT) or [[Destination Therapy]] (DT). Currently, the top three companies in this field are:
A '''left ventricular assist device''' or '''LVAD''' is a [[pump]] which runs in parallel with a [[heart]] to boost the blood flow. The main reason for a patient to have a LVAD implanted is for [[bridge to transplant]] (BTT) or [[destination therapy]] (DT). Currently, the top three companies in this field are:
#[[Thoratec]] - Heartmate2 market capital $2B US
#[[Thoratec]] - Heartmate2 market capital $2B US
#[[Ventracor]] - VentrAssist
#[[Ventracor]] - VentrAssist
#[[Heartware]]
#[[Heartware]]

Latest revision as of 19:27, 2 October 2013

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

A left ventricular assist device or LVAD is a pump which runs in parallel with a heart to boost the blood flow. The main reason for a patient to have a LVAD implanted is for bridge to transplant (BTT) or destination therapy (DT). Currently, the top three companies in this field are:

  1. Thoratec - Heartmate2 market capital $2B US
  2. Ventracor - VentrAssist
  3. Heartware